HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3

Vanni Borghi, Massimo Puoti, Cristina Mussini, Stefania Bellelli, Claudio Angeletti, Francesca Sabbatini, Francesca Prati, Andrea Cossarizza, Roberto Esposito

Research output: Contribution to journalArticle

Abstract

Background: Liver steatosis is a common finding in hepatitis C virus (HCV) infection and is associated with an increased progression of the disease. However, HCV genotype 3 steatosis presents a peculiar and virus-induced pathogenesis. We analysed the effect of HIV coinfection and antiretroviral therapy on hepatic steatosis and the effect of the steatosis on fibrosis in patients with or without HCV genotype 3 infection. Methods: All consecutive HIV-infected and uninfected patients who had undergone a liver biopsy for evaluation of HCV infection at the Infectious Diseases Clinic (Modena, Italy) were included in this study. Primary outcomes were the presence or absence of steatosis or the presence of moderate or advanced fibrosis. Results: A total of 284 patients were enrolled: 187 infected by HCV and 97 coinfected with HIV and HCV. In HCV genotype 3 patients, only HCV-related variables, such as plasma HCV RNA levels (odds ratio [OR] per log10 1.68, P

Original languageEnglish
Pages (from-to)1057-1065
Number of pages9
JournalAntiviral Therapy
Volume13
Issue number8
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3'. Together they form a unique fingerprint.

  • Cite this

    Borghi, V., Puoti, M., Mussini, C., Bellelli, S., Angeletti, C., Sabbatini, F., Prati, F., Cossarizza, A., & Esposito, R. (2008). HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3. Antiviral Therapy, 13(8), 1057-1065.